Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 10, 2017, Pages 1557-1564.e1

  Christensen, Britt ^a,b,d   Hanauer, Stephen B ^c   Erlich, Jonathan ^a   Kassim, Olufemi ^a   Gibson, Peter R ^b   Turner, Jerrold R ^a   Hart, John ^a   Rubin, David T ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b MONASH UNIVERSITY   (Australia)

^c NORTHWESTERN UNIVERSITY   (United States)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Histopathology; Inflammatory Bowel Disease; Mucosal Healing; Normalization

Indexed keywords

ADULT; ARTICLE; CALCULATION; CLINICAL EVALUATION; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSAL DISEASE; NEUTROPHIL CHEMOTAXIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREVALENCE; RECTUM HEMORRHAGE; RECURRENCE FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; SIMPLE CLINICAL COLITIS ACTIVITY INDEX SCORE; ULCERATIVE COLITIS; BIOPSY; CASE CONTROL STUDY; COLON; CYTOCHEMISTRY; DRUG MONITORING; INTESTINE MUCOSA; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

IMMUNOSUPPRESSIVE AGENT;

ADULT; BIOPSY; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; DRUG MONITORING; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85021237082     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2017.02.016     Document Type: Article

References (32)

1. D'Haens, G., Sandborn, W.J., Feagan, B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132 (2007), 763–786.
2. Neurath, M.F., Travis, S.P., Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61 (2012), 1619–1635.
3. Truelove, S.C., Richards, W.C., Biopsy studies in ulcerative colitis. Br Med J 1 (1956), 1315–1318.
4. Froslie, K.F., Jahnsen, J., Moum, B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133 (2007), 412–422.
5. Colombel, J.F., Rutgeerts, P., Reinisch, W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141 (2011), 1194–1201.
6. Sandborn, W.J., Rutgeerts, P., Feagan, B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137 (2009), 1250–1260.
7. Feagan, B.G., Reinisch, W., Rutgeerts, P., et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 102 (2007), 794–802.
8. Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1328.
9. Riley, S.A., Mani, V., Goodman, M.J., et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut 32 (1991), 174–178.
10. Bessissow, T., Lemmens, B., Ferrante, M., et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 107 (2012), 1684–1692.
11. Bitton, A., Peppercorn, M.A., Antonioli, D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120 (2001), 13–20.
12. Park, S., Abdi, T., Gentry, M., et al. Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 111 (2016), 1692–1701.
13. Rubin, D.T., Huo, D., Kinnucan, J.A., et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 11 (2013), 1601–1608.
14. Gupta, R.B., Harpaz, N., Itzkowitz, S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133 (2007), 1099–1105.
15. Hefti, M.M., Chessin, D.B., Harpaz, N.H., et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 52 (2009), 193–197.
16. Bryant, R.V., Burger, D.C., Delo, J., et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 65 (2016), 408–414.
17. Peyrin–Biroulet, L., Bressenot, A., Kampman, W., Histologic remission: the ultimate therapeutic goal in ulcerative colitis?. Clin Gastroenterol Hepatol 12 (2014), 929–934.
18. Feagins, L.A., Melton, S.D., Iqbal, R., et al. Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 18 (2013), 1477–1482.
19. Geboes, K., Riddell, R., Öst, A., et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47 (2000), 404–409.
20. Marchal-Bressenot, A., Salleron, J., Boulagnon-Rombi, C., et al. Development and validation of the Nancy histological index for UC. Gut 66 (2017), 43–49.
21. Mosli, M.H., Feagan, B.G., Zou, G., et al. Development and validation of a histological index for UC. Gut 66 (2017), 50–58.
22. Odze, R., Antonioli, D., Peppercorn, M., et al. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 17 (1993), 869–875.
23. Satsangi, J., Silverberg, M., Vermeire, S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55 (2006), 749–753.
24. Scherl, E.J., Pruitt, R., Gordon, G.L., et al. Safety and efficacy of a new 3.3 g bid tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo- controlled study. Am J Gastroenterol 104 (2009), 1452–1459.
25. Walmsley, R.S., Ayres, R.C., Pounder, R.E., et al. A simple clinical colitis activity index. Gut 43 (1998), 29–32.
26. Kleer, C.G., Appelman, H.D., Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol 22 (1998), 983–989.
27. Levine, T.S., Tzardi, M., Mitchell, S., et al. Diagnostic difficulty arising from rectal recovery in ulcerative colitis. J Clin Pathol 49 (1996), 319–323.
28. Bernstein, C.N., Shanahan, F., Anton, P.A., et al. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc 42 (1995), 232–237.
29. Solberg, I.C., Lygren, I., Jahnsen, J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort. Scand J Gastroenterol 44 (2009), 431–440.
30. U.S. Department of Health and Human Services Food and Drug Adminstration Center for Drug Evaluation and Research (CDER). Ulcerative colitis: clinical trial endpoints guidance for industry. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm515143.pdf. Accessed September 4, 2016.
31. Mikolajczyk, A.E., Watson, S., Ackerman, M.T., et al. Assessment of the degree of variation of histologic inflammation in ulcerative colitis. Gastroenterology, 146, 2014 S-232.
32. Hanauer, S., Schwartz, J., Robinson, M., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 88 (1993), 1188–1197.